E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers |
Terved vabatahtlikud |
|
E.1.1.1 | Medical condition in easily understood language |
Healthy volunteers |
Terved vabatahtlikud |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to test whether exenatide (10 micrograms s.c) stimulates ACTH /cortisol release and what is the magnitude of cortisol response in healthy volunteers. If the response is comparabele to the responses reported during glucagon stimulation test, there is a potential to use the drug to test for secondary adrenal insufficiency. |
Eesmärgiks on uurida tervetel vabatahtlikel, kas eksenatiidi manustamine kutsub esile AKTH ja kortisooli tasemete olulise kõrgenemise. Juhul kui efekti tugevus on sarnane teaduskirjanduses publitseeritud glükagooni stimulastioonitestil saadud tulemustega, oleks eksenatiidi võimalik kasutada tsentraalse neerupealiste puudulikkuse testina. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Ei ole kohaldatav |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Age 18-50 years 2) Bodyweight >65 kg |
1) Vanus 18-50 aastat 2) Kehakaal >65 kg |
|
E.4 | Principal exclusion criteria |
1) Existence of chronic disease 2) Existence of drugs used daily 3) Pregnancy, lactation 4) Use of oral contraceptives during two month before the study |
1) Kroonilise haiguse olemasolu 2) Igapäevaselt tarvitatavate ravimite olemasolu 3) Rasedus, imetamine 4) Suukaudsete kontratseptiivide kasutamine eelneva 2 kuu jooksul |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Maximum level of cortisol after single exenatide injection |
Maksimaalne kortisooli tase peale eksenatiidi ühekordset manustamist |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The blood samples for measuring cortisol level are taken before the exenatide injection and 30, 60, 90 and 120 minutes after the administration. |
Vereanalüüsid kortisooli määramiseks võetakse enne eksenatiidi manustamist ja 30, 60, 90 ning 120 minutit peale seda. |
|
E.5.2 | Secondary end point(s) |
Levels of other related hormonal and biochemical markers and changes in heart rate and blood pressure after exenatide single administration (incl. glucose, ACTH). |
Teiste seotud hormonaalsete ja biokeemiliste markerite tasemed ja muutused südame löögisageduses ning vererõhus peale eksenatiidi manustamist (sh glükoos, AKTH). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The blood samples for measuring hormonal and biochemical markers are taken and blood pressure and heart rate are measured before the exenatide injection and 30, 60, 90 and 120 minutes after the administration. |
Vereanalüüsid hormonaalsete ja biokeemiliste markerite määramiseks võetakse ning vererõhku ja südame löögisageduse väärtused mõõdetakse enne eksenatiidi manustamist ja 30, 60, 90 ning 120 minutit peale seda. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |